CorMatrix Cardiovascular: Healing the Heart
CorMatrix Cardiovascular: Healing the Heart
World Leader in Cardiovascular Regeneration


CorPatch® Epicardial Repair

Indications For Use:

CorPatch® is intended for epicardial tissue support and repair.

  • CorPatch acts as a decellularized ECM® (extracellular matrix) scaffold for supporting repair of weak tissue during cardiac surgery 
  • CorPatch ECM® scaffold allows the patient’s own cells to migrate and attach within the ECM to naturally support and rebuild weakened cardiac tissue

Epicardial Support and Repair

Product Information

CorPatch®, Epicardial Patch 5 PACK

  • 5cm x 5cm: CMCP5P-055
  • 7cm x 10cm: CMCP5P-710


CorTricuspid ECM® Valve

With potential to:

  • Replace, regenerate and restore tricuspid valve
  • Match native valve dimensions with various size options
  • Encourage vessel regeneration to revascularize tissue
  • Rebuild tissue by incorporating patient’s own cells

Cardiac Valve Replacement and Regeneration

CorMatrix® CorTricuspid ECM® Pivotal  Study

CorMatrix CorTricuspid ECM Valve Study is designed to demonstrate the clinical safety and performance of the CorTricuspid ECM Valve for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric subjects with TR. 

Up to 110 subjects at up to 15 study sites will undergo tricuspid valve replacement (TVR) with the CorTricuspid ECM Valve for the surgical management of tricuspid valve disease or dysfunction. 

CorTricuspid Valve Repair and Regeneration Process

CorMatrix Pipeline Projects


CorMatrix® News

  • CorMatrix® Cardiovascular Receives  FDA Approval for Landmark Pivotal Trial for a Regenerative Heart Valve | Learn More

CorMatrix® Events

  • CorMatrix® Presentation | View it Now
  • KOL Webinar on a Novel Approach to Cardiovascular Treatment: CorMatrix’s ECM Technology | View it Now
Register for News


CorMatrix® Cardiovascular

CorMatrix is the world leader in cardiovascular regeneration, addressing the largest challenges in cardiovascular disease, including valvular heart disease, structural heart disorders and myocardial infarction.

It is developing the CorTricuspid ECM® Valve for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric subjects.

The company is also expanding its epicardial repair program with its FDA cleared CorPatch® epicardial repair product. CorPatch® is a second-generation extracellular matrix device engineered for epicardial placement for support and repair of weakened areas of the heart after myocardial infarction.

Tricuspid Valve Regurgitation (TR)

TR is a type of valvular heart disease or dysfunction in which the tricuspid valve of the heart does not close completely, allowing blood to flow backwards from the right ventricle to the right atrium. As severity increases, TR can lead to lower quality of life and increase mortality. 

CorMatrix® Cardiovascular Leaders

John Engels, CorMatrix Cardiovascular

John P. Engels, MBA


  • Successful business, operations, and commercial leader
  • Deep knowledge of biologic, ECM device and regulations
  • History of successful capital raises and company exits 
Robert Matheny, MD, CorMatrix Cardiovascular

Robert Matheny, M.D.

Co-Founder, CTO

  • Expertise in regenerative medicine, and cardiac surgery
  • Strong surgical expertise and KOL relationships
  • Numerous patents, inventions and product launches